MichaelS.BlaissMD
Allergy & Immunology • Roswell, GAExecutive Medical Director, American College of Allergy, Asthma, and Immunology
Dr. Blaiss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1090 Windfaire Pl
Roswell, GA 30076Phone+1 901-674-6075
Education & Training
Tulane UniversityFellowship, Allergy and Immunology, 1980 - 1982
University of TennesseeResidency, Pediatrics, 1978 - 1979- University of TennesseeResidency, Pediatrics, 1977 - 1977
University of Tennessee Health Science Center College of MedicineClass of 1976
Certifications & Licensure
GA State Medical License 2012 - 2025
TN State Medical License 1977 - 2018
MS State Medical License 2004 - 2016- American Board of Allergy and Immunology Allergy & Immunology
- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
- Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology
Publications & Presentations
PubMed
- Pharmacokinetic and Pharmacodynamic Profile of Epinephrine Nasal Spray Versus Intramuscular Epinephrine Autoinjector in Healthy Adults.Matthew Greenhawt, Jay Lieberman, Michael Blaiss, David I Bernstein, John Oppenheimer
The Journal of Allergy and Clinical Immunology. in Practice. 2024-12-01 - Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence-Assisted ARIA Care Pathways (ARIA 2024).Jean Bousquet, Holger J Schünemann, Bernardo Sousa-Pinto, Torsten Zuberbier, Alkis Togias
The Journal of Allergy and Clinical Immunology. in Practice. 2024-10-01 - How to diagnose IgE-mediated food allergy.Jay Lieberman, Antonella Muraro, Michael Blaiss
Archives of Disease in Childhood. Education and Practice Edition. 2024-09-19
Press Mentions
A New Treatment for Severe Allergic Reactions — Without the NeedleAugust 19th, 2024- U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for AdolescentsJanuary 25th, 2023
- Covid-19: Ciclesonide Failed to Accelerate Recovery in Mild DiseaseNovember 25th, 2021
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
